Designed by Scientists for Scientists
We can’t take all the unpredictability out of life. But that will never stop us from trying.
What’s on the minds of the scientists shaping the future of healthcare? Join Radence and the answer could be: You.
Precision and Purpose
Transforming Human Health with Advanced Science
Personalized healthcare today. Global impact tomorrow.
For your life. For your life’s purpose.
Leadership
David Medvedeff, PharmD, MBA
CEO
Dr. David Medvedeff is the CEO of Radence and a seasoned leader in healthcare innovation. He co-founded and served as CEO of Aspen RxHealth, which was acquired by MedImpact. David previously led several successful companies, including Gold Standard, Avatar International, and VUCA Health. Each was acquired by major industry players. Known for driving growth and delivering impact, David has received numerous honors, including the National Prescott Award and the Next Generation Pharmacist Technology Innovator Award. He is also the only two-time recipient of the Pinnacle Award from the American Pharmacists Association Foundation, recognizing lasting contributions to the healthcare field.
Julie Chen, MD
Chief Medical Officer
Dr. Julie Chen is the Chief Medical Officer at Radence. She previously served as Chief Medical Officer at companies such as Human Longevity and Vitagene. Her research, at the FDA, NIH, National Cancer Institute, USC, and Mount Sinai, has shaped scientific advancement in precision medicine. As a fellowship-trained integrative internal medicine physician, she developed numerous corporate wellness programs in Silicon Valley focusing on whole-systems approach to healthcare. Dr. Chen is a frequent medical expert on major media outlets, including ABC, NBC, FOX, and MSN, and she has been featured in national magazines and podcasts. In 2023, she was named one of the Top 25 Women Leaders in Biotechnology by Healthcare Technology Report for her leadership in health tech development. Dr. Chen is a member of the Buck Institute's President's Circle, dedicated to advancing research in aging and longevity.
Erica S. Kasel, MBA
Chief Marketing Officer
Erica S. Kasel, Chief Marketing Officer at Radence, is an award-winning luxury marketing leader. With extensive experience in brand-building, consumer engagement, and growth, she has held senior roles at top global brands, including Chanel, Leading Hotels of the World, and American Express. At AmEx, Erica led Departures Magazine's record revenue growth and launched Centurion magazine. She has also served as adjunct faculty at NYU and Lynn University, guest lectured at Cornell, IMHI/ESSEC, and Columbia University, and she is an Executive-in-Residence at The Luxury Education Foundation MBA program. Erica is a board member of The Palm Beaches Tourism and The Center for Arts and Innovation.
Wuhong Li, MS
Chief Technology Officer
Wuhong Li, Chief Technology Officer at Radence, is an award-winning technology leader and healthcare innovator. With a proven track record in patient care, clinical decision support, health informatics, and data intelligence, he has co-founded and led multiple PE/VC-backed digital health companies. Wuhong has successfully built and scaled teams across software engineering, cloud infrastructure, IT operations, and security. His innovative contributions have earned recognition from Microsoft, Computerworld, HIMSS, and Great Entrepreneurs, which named him one of the Top 25 Entrepreneurs of Tampa for 2024.
Sarah Pesce, ANP, MSCDL
Chief Operating Officer
Sarah Pesce is the Chief Operating Officer at Radence. She previously served as COO of Thorne Lab, a division of Thorne HealthTech, where she led the development of a clinical platform offering a comprehensive, 360-degree view of individual health. Prior to Thorne, Sarah was COO of Lab100 at Mount Sinai Medical Center, where she shaped clinical operational strategies for advanced digital screening assessments. She also served as Senior Director of Business Development and Clinical Operations for Mount Sinai’s Executive Health Program and worked as Nurse Practitioner for Dr. Valentine Fuster, managing complex cardiology patients and launching impactful ambulatory programs.
Clinical Advisory Board
Fanny Elahi, MD, PhD
Neurologist
Dr. Fanny Elahi is a physician-scientist and Associate Professor in the Departments of Neurology, Neuroscience, and Pathology at the Icahn School of Medicine at Mount Sinai in New York City. She serves as Director of Fluid Biomarker Research at the Barbara and Maurice Deane Center for Wellness and Cognitive Health and is one of the leaders at the Alzheimer's Disease Research Center, where she co-directs the Genetics and Genomics Core and oversees the development of novel blood biomarkers for neurodegenerative diseases. She also has an appointment at the James J. Peters Department of Veterans Affairs Medical Center. Dr. Elahi's research is pushing the boundaries of methods and approaches and breaking down silos to move the needle on therapeutic discoveries for dementia with a focus on genetic diseases, such as CADASIL. By combining molecular techniques with clinical data, and advanced data analytics, her multidisciplinary research program is studying the link between blood vessel disease and neurodegeneration. A major focus is the development of blood biomarkers and the combination of markers with in vitro models of disease to advance understanding of disease mechanisms and identification of novel drug targets. She is passionate about translating laboratory findings into clinical applications, and drug discovery for dementia-causing diseases.
Zahi A. Fayad, MS, PhD
Biomedical Engineer
Dr. Zahi A. Fayad serves as the Lucy G. Moses Professor of Medical Imaging and Bioengineering at the Icahn School of Medicine at Mount Sinai. He is Professor of Radiology (vice-chair for research) and Professor of Medicine (Cardiology). He is the founding Director of the BioMedical Engineering and Imaging Institute. Dr. Fayad's research has been dedicated to the detection and prevention of cardiovascular disease with many seminal contributions in the field of multimodality biomedical imaging (MR, CT, PET and PET/MR) and nanomedicine. Recent collaborative work has been in: 1) the study of psychosocial stress exposure in the brain, the cardiovascular system and the immune system; 2) the development of platform nanotechnology to produce nanobiologics for immunotherapy in multiple disease conditions; 3) the development of the Mount Sinai Imaging Research Warehouse (de-identified, pseudo-anonymized images and metadata) as a unique repository of radiological imaging big data for focused imaging and general healthcare research. Dr. Fayad had his engineering trainings at Bradley University (BS, Electrical Engineering '89), the Johns Hopkins University (MS, Biomedical Engineering '91), and at the University of Pennsylvania (PhD Bioengineering '96). From 1996 to 1997 he was junior faculty in the Department of Radiology at the University of Pennsylvania. In 1997 he joined the faculty at the Mount Sinai School of Medicine as Assistant Professor in Radiology and Medicine (Cardiology).
Nicholas A. Marston, MD
Cardiologist
Dr. Nicholas Marston graduated summa cum laude from the University of Texas at Austin and earned his medical degree from the University of Minnesota. He completed his internship, residency, and chief medical residency in internal medicine at the University of California San Diego. Dr. Marston went on to complete a fellowship in cardiovascular medicine at the Brigham and Women’s hospital, where he also served as chief cardiology fellow. He is now a cardiologist at Brigham and Women’s and an Investigator at the TIMI Study Group. His research interests include novel lipid-lowering therapies, genetics of cardiovascular disease, and the application of biomarkers and genetic variants to identify high-risk patients for targeted therapy.
Christopher Mason, PhD
Geneticist
Dr. Christopher Mason is an Associate Professor of Genomics, Physiology, and Biophysics at Weill Cornell Medicine and the Director of the WorldQuant Initiative for Quantitative Prediction. He also holds affiliate appointments at the Tri-I Program on Computational Biology and Medicine (Cornell, Memorial Sloan Kettering Cancer Center and Rockefeller University), Harvard Medical School, and Yale Law School. His lab develops and deploys new biochemical and computational methods in functional genomics to elucidate the genetic basis of human disease and physiology. The lab creates and deploys novel techniques in next-generation sequencing and algorithms for: tumor evolution, genome evolution, DNA and RNA modifications, and genome/epigenome engineering. Dr. Mason’s lab also works closely with NIST/FDA to build international standards for these methods (SEQC2, IMMSA, and Epigenomics QC groups), to ensure clinical-quality genome measurements and editing. His lab also works with NASA to build integrated molecular portraits of genomes, epigenomes, transcriptomes, and metagenomes for astronauts, which help establish the molecular foundations and genetic defenses for enabling long-term human spaceflight. Dr. Mason has won the NIH's Transformative R01 Award, the NASA Group Achievement Award, and he was named as one of the "Brilliant Ten" Scientists by Popular Science, featured as a TEDMED speaker, and called "The Genius of Genetics" by 92Y.
Jacob Oppenheim, PhD
Biomathematician, Bioinformatic, and Computational Biologist
Dr. Jacob Oppenheim is a Venture Partner at RA Ventures (RAVen), focusing on new company creation. Prior to joining RAVen. Dr. Oppenheim was an Entrepreneur-in-Residence at Digitalis Ventures and co-founded Fresnel, a ‘Bloomberg for Biology’ platform. He previously served as Vice President of Data Science and Engineering at EQRx, where he led the development of data strategy and implementation of scalable data infrastructure. Dr. Oppenheim also held leadership roles at Indigo, including Senior Director of Data Science, where he developed machine learning systems for agriculture applications. He holds extensive experience in building and scaling high-performing cross-functional teams in data science, engineering, and product development, with a focus on applying AI/ML to biological problems. Dr. Oppenheim has presented at top conferences and is named on multiple patent applications in the field. He holds a PhD in Biological Physics from Rockefeller University and an AB in Physics from Princeton University.